Hyatt Discloses Exclusive Discussions With Playa Hotels & Resorts N.V.

Submitted by Anonyme on 2024-12-23T12:40:00+01:00

Hyatt Hotels Corporation (the “Company” or “Hyatt”) (NYSE: H) today disclosed it has executed an exclusivity agreement with Playa Hotels & Resorts N.V. (“Playa”) (NASDAQ: PLYA) under which Playa has agreed to negotiate exclusively with Hyatt regarding potential strategic alternatives, which may include the acquisition of Playa by Hyatt.


Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases

Submitted by Anonyme on 2024-12-23T13:10:02+01:00

Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office: Minato-ku, Tokyo), a wholly-owned subsidiary of H.U. Group Holdings, Inc. (Chairman, President and Group CEO: Shigekazu Takeuchi; Head Office: Minato-ku, Tokyo), and Eisai Co., Ltd. (Representative Corporate Officer and CEO: Haruo Naito; Head Office: Bunkyo-ku, Tokyo; hereinafter "Eisai") announced today that they have entered into a memorandum of understanding for the joint research and social implementation of novel blood-based biomarkers in the field of neurodegenerative diseases.


Shiyi Zhou Joins Watlow® as Regional President for Asia

Submitted by Anonyme on 2025-01-06T23:19:50+01:00

Watlow®, a leading provider of industrial technology and thermal systems, welcomes Shiyi Zhou as its new regional president of Asia. Reporting directly to Rob Gilmore, Watlow’s chief executive officer (CEO), Zhou is responsible for the growth and profitability of Watlow in Asia. He is a member of Watlow’s executive team.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250106938045/en/

15/01/2025 22:30
Mainstay Medical Announces Positive Outcomes from Landmark RESTORE Clinical Trial of ReActiv8®

Mainstay Medical Holdings plc today announced the publication of positive one-year primary assessment results of the RESTORE randomized clinical trial of ReActiv8 for the treatment of intractable chronic low back pain. The data show that the addition of ReActiv8 Restorative Neurostimulation therapy to current standard of care results in superior improvements in back pain-related disability, pain and quality of life compared to standard of care treatments alone. The results were published in Pai...

Subscribe to